14:21 , May 20, 2019 |  BC Innovations  |  Distillery Therapeutics

WWP1 inhibitor for MYC-driven prostate cancer

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer In vitro and mouse studies identified a WWP1 inhibitor that could help treat MYC-driven prostate cancer. In a mouse model of MYC-overexpressing prostate cancer, systemic knockout of WWP1 or...
18:51 , May 15, 2019 |  BC Extra  |  Company News

Vertex moving into protein degradation with Kymera collaboration

In another move to expand its suite of modalities to address serious diseases, Vertex has partnered with Kymera to develop targeted small molecule protein degraders under a four-year deal. Kymera Therapeutics LLC (Cambridge, Mass.) will...
12:35 , May 8, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

New Therapeutic Targets and Biomarkers: April 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April. Therapeutic targets are defined as any protein, gene or other molecule...
10:08 , Apr 30, 2019 |  BioCentury  |  Finance

How Nextech-led round will help Vividion to POC

After identifying three lead programs with its proteome-wide small molecule screening platform, San Diego-based Vividion has raised $82 million in an oversubscribed series B round led by new investor Nextech Invest. Now flush with over...
19:55 , Apr 11, 2019 |  BC Innovations  |  Emerging Company Profile

Nurix: Two sides of protein degradation

Nurix is flipping the concept of targeted protein degradation on its head. In addition to the usual approach of inducing target destruction, the company has technology that can block E3 ligase activity and increase a...
13:55 , Apr 10, 2019 |  BC Innovations  |  Distillery Therapeutics

UBR7 and CDH4 as targets for triple-negative breast cancer

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest UBR7 or its downstream mediator CDH4 could help treat triple-negative breast cancer (TNBC). In tumor samples from patients with TNBC or...
21:49 , Apr 2, 2019 |  BC Innovations  |  Distillery Therapeutics

Microbial lysine-tRNA ligase inhibitor for malaria and Cryptosporidium

DISEASE CATEGORY: Infectious disease INDICATION: Malaria; Cryptosporidium In vitro , cell culture and mouse studies identified a chromene carboxamide-based inhibitor of P. falciparum lysine-tRNA ligase and Cryptosporidium lysine-tRNA ligase that could help treat malaria and...
20:55 , Apr 1, 2019 |  BC Extra  |  Financial News

Bridge raises $27.2M series C led by UTC, Shinhan

Bridge has parlayed a partnership with Daewoong on the South Korean biotech’s lead ulcerative colitis asset into a W31 billion ($27.2 million) series C round, which was led by returning investor UTC Investment Co. and...
20:41 , Mar 7, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: February 2019

New Therapeutic Targets and Biomarkers: February 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during February. Therapeutic targets are defined as any protein, gene or other molecule...
01:48 , Mar 1, 2019 |  BC Innovations  |  Translation in Brief

Targeting pathogenic Th17 cells

A recent pair of studies offers two new approaches to treating autoimmune diseases that go after the source of Th17-mediated inflammation. T helper type 17 (Th17) cells are effector T cells that secrete the cytokine...